科兴制药：2025年上半年净利润8034.45万元 同比增长576.45%

Financial Performance - For the first half of 2025, the company's operating revenue was approximately 700.46 million, a decrease from 759.89 million in the same period last year, representing a decline of about 7.5% [2] - The total profit for the same period was approximately 84.13 million, significantly up from 41.98 million year-on-year, indicating an increase of about 100% [2] - The net profit attributable to shareholders was approximately 80.34 million, compared to 11.88 million in the previous year, marking an increase of about 576% [2] - The net profit after deducting non-recurring gains and losses was approximately 45.28 million, up from 21.53 million, reflecting an increase of about 109% [2] - The net cash flow from operating activities was approximately 29.80 million, a substantial improvement from a negative cash flow of 34.03 million in the same period last year [2] Financial Ratios - As of August 22, 2025, the company's price-to-earnings (P/E) ratio (TTM) was approximately 89.61, the price-to-book (P/B) ratio (LF) was about 5.32, and the price-to-sales (P/S) ratio (TTM) was around 6.65 [2] Shareholder Structure - The top ten circulating shareholders as of the end of the first half of 2025 included new shareholders such as E Fund Medical Biotechnology Stock Fund and Fortune Tianhui Selected Growth Mixed Fund, replacing previous shareholders [53] - The shareholding proportions of E Fund Medical Health Mixed Fund and Fortune Precision Medical Flexible Allocation Mixed Fund increased, while the holdings of Shenzhen Keyi Medical Holdings and others decreased [53][54] Asset and Liability Changes - As of the end of the first half of 2025, the company's trading financial assets accounted for 5.22% of total assets, up from 0% at the end of the previous year [41] - Long-term borrowings increased by 13.96%, contributing to a rise in the proportion of total assets [44] - The company's inventory value was approximately 1.29 million, accounting for 7.66% of net assets, which decreased from the previous year [47] Profitability Metrics - The weighted average return on equity for the first half of 2025 was 4.8%, an increase of 4.07 percentage points year-on-year [25] - The return on invested capital for the same period was 3.28%, up by 2.79 percentage points compared to the previous year [25]